Centre Hospitalier de Longjumeau, France Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2014
NCT03766295
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Centre Hospitalier de Longjumeau, France | Groupe Hospitalier Nord Essonne - Longjumeau

Active Ingredients

Drugs in Phase 3 Trials (2)

gemcitabine (gemzar) (1 trial)

masitinib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pancreatic Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2